Oral JAK inhibitor baricitinib effective in JIA

被引：0
|
作者：
Jessica McHugh
机构：
[1] Nature Reviews Rheumatology,
来源：
Nature Reviews Rheumatology | 2023年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In a phase III trial, the oral Janus kinase inhibitor baricitinib was safe and effective in patients with juvenile idiopathic arthritis who previously had an inadequate response to DMARD therapy.
引用
收藏
页码：539 / 539
相关论文
共 50 条
  • [21] Pharmacokinetics (PK), Pharmacodynamics (PD), and Proposed Dosing of Oral Janus Kinase (JAK) 1 and JAK2 Inhibitor Baricitinib in Patients with IFN-Mediated Autoinflammatory Diseases (AIDs)
    Kim, Hanna
    Brooks, Kristina M.
    Wakim, Paul
    Blake, Mary
    Brooks, Stephen R.
    Sanchez, Gina A. Montealegre
    de Jesus, Adriana Almeida
    Huang, Yan
    Tsai, Wanxia Li
    Gadina, Massimo G.
    Kumar, Parag
    Goldbach-Mansky, Raphaela
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [22] JAK inhibitor Baricitinib Attenuates Kidney Injury in Sepsis Model Induced by Cecal Ligation and Puncture
    Tarakci, Betul
    Firat, Semanur
    Cakir, Murat
    Bircan, Burak
    Sekerci, Guldeniz
    Aydin, Ali
    ACTA PHYSIOLOGICA, 2025, 241 : 76 - 76
  • [23] COMPARISON OF EFFICACY AND SAFETY IN JAK INHIBITOR DUE TO A DIFFERENCE OF SELECTIVITY - TOFACITINIB VS. BARICITINIB -
    Yoshii, I.
    Sawada, N.
    Chijiwa, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1318 - 1319
  • [24] Accidental exposure to the JAK-inhibitor baricitinib during pregnancy in Rheumatoid Arthritis: A case report
    Costanzo, G.
    Firinu, D.
    Losa, F.
    Deidda, M.
    Barca, M. P.
    Messina, M. R.
    Del Giacco, S.
    ALLERGY, 2020, 75 : 477 - 477
  • [25] JAK inhibitor Baricitinib Attenuates Kidney Injury in Sepsis Model Induced by Cecal Ligation and Puncture
    Tarakci, Betul
    Firat, Semanur
    Cakir, Murat
    Bircan, Burak
    Sekerci, Guldeniz
    Aydin, Ali
    ACTA PHYSIOLOGICA, 2025, 241
  • [26] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [27] Oral surveillance and JAK inhibitor safety: the theory of relativity
    Kevin L. Winthrop
    Stanley B. Cohen
    Nature Reviews Rheumatology, 2022, 18 : 301 - 304
  • [28] Oral surveillance and JAK inhibitor safety: the theory of relativity
    Winthrop, Kevin L.
    Cohen, Stanley B.
    NATURE REVIEWS RHEUMATOLOGY, 2022, 18 (05) : 301 - 304
  • [29] Safety profile of JAK inhibitors: a focus on baricitinib
    Cohen, Stanley B.
    LANCET RHEUMATOLOGY, 2020, 2 (06): : E313 - E314
  • [30] Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy
    Handa, Shivani
    Sivakumar, Ganesh
    Srisuwananukorn, Andrew
    Dueck, Amylou
    Tremblay, Douglas
    Mascarenhas, John
    Ginzburg, Yelena
    Kremyanskaya, Marina
    Hoffman, Ronald
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : e314 - e319
12345